Phospho-AKT (Ser473) Monoklonaler Antikörper

Phospho-AKT (Ser473) Monoklonal Antikörper für WB

Wirt / Isotyp

Maus / IgG1

Getestete Reaktivität

human, Maus

Anwendung

WB

Konjugation

HRP Fluorescent Dye

CloneNo.

1C10B8

Kat-Nr. : HRP-66444

Synonyme

AKT, AKT1, PKB, PKB ALPHA, PRKBA, Protein kinase B, Proto oncogene c Akt, RAC, RAC ALPHA, RAC PK alpha

---

Galerie der Validierungsdaten

• 

  WB analysis of HEK-293 using HRP-66444

  Untreated and Calyculin A treated HEK-293 cells were subjected to SDS PAGE followed by western blot with HRP-66444 (Phospho-AKT (Ser473) antibody) at dilution of 1:16000 incubated at room temperature for 1.5 hours.

---

Geprüfte Anwendungen

• Erfolgreiche Detektion in WB: Mit Calyculin A behandelte HEK-293-Zellen

Empfohlene Verdünnung

• Western Blot (WB): WB : 1:5000-1:50000

Sample-dependent, check data in validation data gallery

Produktinformation

HRP-66444 bindet in WB Phospho-AKT (Ser473) und zeigt Reaktivität mit human, Maus

• Getestete Reaktivität: human, Maus
• Wirt / Isotyp: Maus / IgG1
• Klonalität: Monoklonal
• Typ: Antikörper
• Immunogen: Peptid
• Vollständiger Name: v-akt murine thymoma viral oncogene homolog 1
• Beobachtetes Molekulargewicht: 60-62 kDa
• GenBank-Zugangsnummer: NM_005163
• Gene symbol: AKT1
• Gene ID (NCBI): 207
• Konjugation: HRP Fluorescent Dye
• Form: Liquid
• Reinigungsmethode: Protein-A-Reinigung
• Lagerungspuffer: BS mit 50% Glyzerin, 0,05% Proclin300, 0,5% BSA, pH 7,3.
• Lagerungsbedingungen: Bei -20°C lagern. Vor Licht schützen. Nach dem Versand ein Jahr stabil. Aliquotieren ist bei -20^oC Lagerung nicht notwendig. 20ul Größen enthalten 0,1% BSA.

Hintergrundinformationen

1) What is AKT?

The serine/threonine kinase B AKT pathway (also known as the PI3K-Akt pathway) plays a vital role in the regulation of cellular processes, including cell proliferation, survival, and growth - processes that are essential for oncogenesis. Mutation of the regulator proteins PI3K and PTEN causes uncontrolled disruption within the PI3-kinase pathway, leading to the development of human cancers (1,2; see also AKT pathway poster for more details).

2) phospho-AKT and FAQs

A)  What is the best way to normalize phosphorylated proteins analyzed by western blot?
Normalize phospho-AKT and total AKT with your loading control (e.g. Actin, tubulin), then calculate the phospho/total ratio using these normalized values.  
Put more simply:
1. Calculate the ratio of band intensities of a phospho-AKT band: the loading control.
2. Calculate the ratio of band intensities of total AKT: loading control.
3. Divide ratio obtained #1 by #2 to obtain a normalized value for comparison among different conditions. This procedure allows one to distinguish between a change in AKT expression and a change in the ratio of phospho-AKT.
* If you are looking at the differences in a phospho-AKT expression resulting from an experimental condition (e.g., knockdown), you should also show the expression of total AKT to distinguish between a change in AKT expression (transcription/translation level) and a change in the AKT phosphorylation status.
B) What is the observed molecular weight for AKT and phospho-AKT?
Molecular Weight AKT - 56 kDa
Molecular Weight phospho-AKT - 60 kDa (Figure 1)
  

Figure 1. WB: HEK-293 cell lysate was subjected to SDS PAGE followed by western blot with 60203-2-Ig (AKT antibody) and 66444-1-Ig (AKT-phospho-S473 antibody) at a dilution of 1:4000 incubated at room temperature for 1.5 hours.

C) Are there any special WB conditions to optimize staining of a phospho-AKT?
Since this is a phosphorylated protein, 5% BSA is recommended over non-fat milk as a blocking agent.
D) What are good positive and negative controls for a phospho-AKT?
- Positive Control: HEK293 cells
- Negative Control: Treatment with PI3K inhibitors (e.g. wortmannin)
E) What species does this antibody react with?

Our internal testing has confirmed that it reacts with the human and mouse forms of phospho-AKT.Reactivity with the human form is also supported by the literature's citations of this antibody.

References:

1. Perturbations of the AKT signaling pathway in human cancer.
2. Targeting the PI3K-Akt pathway in human cancer: rationale and promise.